We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
deCODE Chemistry Initiates Chemical Development Collaboration with PolyMedix
News

deCODE Chemistry Initiates Chemical Development Collaboration with PolyMedix

deCODE Chemistry Initiates Chemical Development Collaboration with PolyMedix
News

deCODE Chemistry Initiates Chemical Development Collaboration with PolyMedix

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "deCODE Chemistry Initiates Chemical Development Collaboration with PolyMedix"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

deCODE chemistry has initiated a new chemical development service collaboration with PolyMedix, Inc.

Under the terms of the collaboration, deCODE’s process chemistry team will develop scalable synthetic routes for a number of products in PolyMedix’s pre-clinical pipeline. Following optimization of these production routes, deCODE will prepare larger-scale quantities of the compounds for pre-clinical development activities. These research activities build upon a successful process research program that was conducted by deCODE for PolyMedix under an earlier collaboration.

“We are very happy to be able to build upon the initial work we performed for PolyMedix, and enter into this broader collaborative relationship,” said Dr. David Zembower, Vice President of Chemistry at deCODE. “Our goal under this expanded collaboration is to help PolyMedix advance their compounds through the pre-clinical development pathway in the most efficient, economical manner possible.”

Advertisement